These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32013313)

  • 1. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases.
    Park SH; Park JC; Lukas M; Kolar M; Loftus EV
    Intest Res; 2020 Jan; 18(1):34-44. PubMed ID: 32013313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.
    Petric Z; Goncalves J; Paixao P
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
    Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
    Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in inflammatory bowel disease.
    Talathi S; Baig KRKK
    J Dig Dis; 2020 Nov; 21(11):610-620. PubMed ID: 32920972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus.
    D'Amico F; Solitano V; Magro F; Olivera PA; Halfvarson J; Rubin D; Dignass A; Al Awadhi S; Kobayashi T; Queiroz NSF; Calvo M; Kotze PG; Ghosh S; Peyrin-Biroulet L; Danese S
    J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37834994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
    Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
    J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017.
    Scott FI; Lichtenstein GR
    Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics.
    Limdi JK; Farraye FA
    Crohns Colitis 360; 2021 Jul; 3(3):otab015. PubMed ID: 36776664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
    Gonczi L; Ilias A; Kurti Z; Lakatos PL
    Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
    Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
    Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of biosimilars in the treatment of inflammatory bowel diseases.
    Park DI
    Intest Res; 2016 Jan; 14(1):15-20. PubMed ID: 26884730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.